An expert oncologist and pathologist discuss molecular testing in metastatic colorectal cancer and the current and upcoming options for HER2-targeted therapies.
June 15th 2022
Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.
July 6th 2022
A pathologist explains how she chooses between a variety of molecular testing technology options in colorectal cancer.
Experts describe which patients should be screened for HER2 amplification in colorectal cancer and how best to detect it.
July 13th 2022
Drs Hechtman and Cercek discuss how practice setting affects molecular testing options and the barriers patients face in receiving testing.
A look at how the molecular testing landscape in colorectal cancer is evolving.
July 22nd 2022
Dr Jaclyn Hechtman presents the profile of a patient with HER2+ metastatic colorectal cancer and has a conversation with Dr Andrea Cercek on how to personalize frontline therapy selection in each patient.
Andrea Cercek, MD, explains the potential treatment options for metastatic colorectal cancer after disease progression.
August 3rd 2022
Dr Andrea Cercek reviews key clinical trials in HER2-amplified colorectal cancer treatment and considers how the approval of new therapies will impact the current treatment landscape.
Experts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.